CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
儿童和年轻成人接受 CD19 靶向治疗后的脑脊液参数
英文原题：Cerebral Spinal Fluid Parameters Following CD19-Targeted Therapies in Children and Young Adults.
查看英文原题
Cerebral Spinal Fluid Parameters Following CD19-Targeted Therapies in Children and Young Adults.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
急性淋巴细胞白血病患者脑脊液中出现白细胞可能提示中枢神经系统复发。CD19靶向免疫治疗可能增加血脑屏障通透性，导致神经毒性并浸润CNS。我们研究了71例连续接受CD19CAR-T 细胞或blinatumomab治疗患者的CSF细胞和蛋白含量。应答患者在blinatumomab或CAR-T 细胞治疗后，细胞增多症的发生率分别为66%和61%。CSF参数与毒性或既往CNS疾病无关。应考虑在免疫治疗后进行常规CSF流式细胞术，以区分T细胞浸润与CNS复发。
展开英文摘要原文
The presence of leukocytes in the cerebral spinal fluid (CSF) of patients with acute lymphoblastic leukemia may indicate a relapse in the central nervous system. CD19-directed immunotherapy may increase the blood-brain barrier permeability, leading to neurologic toxicity and infiltrate the CNS.
We studied the CSF cell and protein content in 71 consecutive patients who received either CD19 chimeric antigen receptor T cells or blinatumomab. Responding patients had an incidence of 66% and 61% of pleocytosis following blinatumomab or chimeric antigen receptor T cells, respectively. CSF parameters did not correlate with toxicity or prior CNS disease. Routine CSF flow cytometry following immunotherapy to distinguish T-cell infiltration from CNS relapse should be considered.
论文信息
- 作者
- Leib S、Bielorai B、Vernitsky H、Aharony-Tevet Y、Toren A、Jacoby E
- 单位
- Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer.
- 文献类型
- 非美国政府资助研究
- 期刊
- Journal of pediatric hematology/oncology2024 Jan 1
- 原文标识
- PubMed 37807185 · DOI 10.1097/MPH.0000000000002765